Cyril Breuker1, Florian Clement2, Thibault Mura3, Valérie Macioce3, Audrey Castet-Nicolas4, Yohan Audurier2, Catherine Boegner5, Emilie Morcrette5, Anne Jalabert2, Maxime Villiet2, Antoine Avignon6, Ariane Sultan6. 1. Clinical Pharmacy Department, University Hospital, Montpellier, France; PhyMedExp, University of Montpellier, CNRS, INSERM, Montpellier, France. Electronic address: c-breuker@chu-montpellier.fr. 2. Clinical Pharmacy Department, University Hospital, Montpellier, France. 3. Clinical Research and Epidemiology Unit, University Hospital, Montpellier, France. 4. Clinical Pharmacy Department, University Hospital, Montpellier, France; IRCM -INSERM U1194, University of Montpellier, Montpellier, France. 5. Endocrinology-Diabetology-Nutrition Department University Hospital, Montpellier, France. 6. PhyMedExp, University of Montpellier, CNRS, INSERM, Montpellier, France; Endocrinology-Diabetology-Nutrition Department University Hospital, Montpellier, France.
Abstract
BACKGROUND: Cardiovascular diseases are the first cause of mortality in patients with diabetes, and LDL-cholesterol is a well-established cardiovascular risk factor. This study aimed to assess rate of LDL-cholesterol target attainment among patients with diabetes at very-high cardiovascular risk treated with statins, and to identify predictive factors of non-attainment of target in this population. METHODS: Patients were recruited in the Nutrition-Diabetes unit of Montpellier University Hospital, France, from 2014 to 2017. We included all consecutive patients with type 1 or type 2 diabetes receiving statin treatment and at very-high cardiovascular risk according to 2016 ESC guidelines, therefore having a LDL-cholesterol target of <1.8 mmol/L. LDL-cholesterol levels were measured upon admission. Variables independently associated with non-attainment of LDL-Cholesterol target were assessed using multivariable logistic regression. RESULTS: 654 patients were included. Mean age was 63.8 years (SD 11.0), 41.9% were women and 42.3% had a history of cardiovascular disease. 59% of patients did not achieve LDL-cholesterol target, with a median value (interquartile range) of 2.4 mmol/L (2.1-2.9) versus 1.4 mmol/L (1.1-1.6) in patients at target. Risk of non-attainment of LDL-cholesterol target value was increased in women (odds ratio [95% confidence interval]: 2.27 [1.62-3.17]) and decreased in patients with history of coronary artery disease (0.64 [0.45-0.89]) or history of stroke or transient ischemic attack (0.59 [0.33-1.07]). CONCLUSIONS: Management of dyslipidemia is suboptimal, even in very-high risk patients with diabetes under statins. Lipid-lowering treatment should be intensified, in particular in very high risk patients with diabetes who are women or in primary cardiovascular prevention. Clinical Trial number: NCT03449784.
BACKGROUND:Cardiovascular diseases are the first cause of mortality in patients with diabetes, and LDL-cholesterol is a well-established cardiovascular risk factor. This study aimed to assess rate of LDL-cholesterol target attainment among patients with diabetes at very-high cardiovascular risk treated with statins, and to identify predictive factors of non-attainment of target in this population. METHODS:Patients were recruited in the Nutrition-Diabetes unit of Montpellier University Hospital, France, from 2014 to 2017. We included all consecutive patients with type 1 or type 2 diabetes receiving statin treatment and at very-high cardiovascular risk according to 2016 ESC guidelines, therefore having a LDL-cholesterol target of <1.8 mmol/L. LDL-cholesterol levels were measured upon admission. Variables independently associated with non-attainment of LDL-Cholesterol target were assessed using multivariable logistic regression. RESULTS: 654 patients were included. Mean age was 63.8 years (SD 11.0), 41.9% were women and 42.3% had a history of cardiovascular disease. 59% of patients did not achieve LDL-cholesterol target, with a median value (interquartile range) of 2.4 mmol/L (2.1-2.9) versus 1.4 mmol/L (1.1-1.6) in patients at target. Risk of non-attainment of LDL-cholesterol target value was increased in women (odds ratio [95% confidence interval]: 2.27 [1.62-3.17]) and decreased in patients with history of coronary artery disease (0.64 [0.45-0.89]) or history of stroke or transient ischemic attack (0.59 [0.33-1.07]). CONCLUSIONS: Management of dyslipidemia is suboptimal, even in very-high risk patients with diabetes under statins. Lipid-lowering treatment should be intensified, in particular in very high risk patients with diabetes who are women or in primary cardiovascular prevention. Clinical Trial number: NCT03449784.
Authors: Jose Javier Gomez-Barrado; Paula Gomez-Turegano; Carolina Ortiz-Cortes; Jorge Vega-Fernandez; Marta Gomez-Turegano; Francisco Javier Garciperez de Vargas; Luis Enrique Lezcano Gort; Zineb Kounka; Benjamin Roque Rodriguez; David Chipayo Gonzales; Paloma Perez-Espejo; Ana Isabel Fernandez-Chamorro; Maria Beltran Moreno; Maria Jose Romero Castro; Maria Victoria Mogollon Jimenez; Gonzalo Marcos Gomez; Yolanda Porras Ramos Journal: Cardiol Res Date: 2020-08-01
Authors: Walter Masson; Melina Huerín; Lorenzo Martin Lobo; Gerardo Masson; Graciela Molinero; Mariano Nemec; Mariela Boccadoro; Cinthia Romero; Gabriel Micali; Daniel Siniawski Journal: J Cardiovasc Dev Dis Date: 2020-02-05
Authors: Jacques Blacher; Amélie Gabet; Alexandre Vallée; Jean Ferrières; Eric Bruckert; Michel Farnier; Valérie Olié Journal: Medicine (Baltimore) Date: 2020-12-11 Impact factor: 1.817